J&J unit wraps up Russian OTC buy; Cephalon shareholders OK Teva deal;

@FiercePharma: Expect more pharma M&A, less pharma hiring. Report | Follow @FiercePharma

> Johnson & Johnson's Cilag unit has completed its $245 million acquisition of some of the most popular OTC cough and cold medicines in Russia. Story

> Cephalon stockholders voted to approve Teva Pharmaceutical Industries' proposal to acquire Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. More

> President Obama's campaign committee moved a fund-raiser from the Pfizer world headquarters to another New York City location after the Boston Globe inquired about the propriety of a Big Pharma firm hosting a benefit for the administration regulating it. Piece

> Goldman Sachs analysts reiterated their "buy" rating on Shire stock, helping to send the U.K. company's shares up to an all-time high. Article

> Despite a net loss, Cubist Pharmaceuticals beat second-quarter expectations with a 5% increase in net sales, to $176.8 million. Release

> EMD Serono said interim president James Hoyes has been permanently appointed to that post. Story

> Global production of seasonal flu vaccine is expected to double to 1.7 billion doses by 2015, with 11 new manufacturers coming onstream in developing countries, the World Health Organization said. News

> President Barack Obama will soon send a free trade pact with South Korea to Congress for approval despite Republican threats to vote against it because of a retraining program for workers displaced by trade. Article

Biotech News

@FierceBiotech: Dendreon, cancer drug developers top slate of buyout candidates. Article | Follow @FierceBiotech

> Roche gearing up to seek approvals of breast cancer treatment. News

> Vical, Astellas ink $130M vaccine licensing deal. Report

And Finally... Internet searches are making information easy to forget, as more people rely on computers as a type of "external memory," a study found. Item

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.